5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

Bibliographic Details
Main Authors:	J. Gligorov, X. Pivot, B. Ataseven, M. De Laurentiis, A. Llombart, K.H. Jung, A. Manikhas, H.A. Azim, A. Alexandrou, K. Gupta, L. Herraez-Baranda, N. Tosti, E. Restuccia
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000977

Similar Items

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
by: Joseph Gligorov, et al.
Published: (2022-08-01)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
by: Shannon McLaughlin, et al.
Published: (2023-01-01)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021-05-01)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
by: J. Lluch-Gómez, et al.
Published: (2023-05-01)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
by: Sibylle Loibl, et al.
Published: (2022-09-01)

Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer
by: Caroline Muñoz, et al.
Published: (2024-03-01)

Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
by: Dukić Nikolina, et al.
Published: (2020-01-01)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
by: Nadine Norton, et al.
Published: (2018-06-01)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
by: McLarty, K, et al.
Published: (2009)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
by: Chau Dang, et al.
Published: (2022-05-01)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
by: Quentin Jacquinot, et al.
Published: (2022-09-01)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
by: Ali Hajjar, et al.
Published: (2019-01-01)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
by: Mohd Nafi, SN
Published: (2014)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
by: Baubek Spanov, et al.
Published: (2022-01-01)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
by: Eleni Triantafyllidi, et al.
Published: (2022-08-01)

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
by: Juin Park, et al.
Published: (2023-12-01)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: Anna Burguin, et al.
Published: (2020-01-01)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
by: Xin Li, et al.
Published: (2018-08-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019-11-01)

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
by: E. V. Lubennikova, et al.
Published: (2017-11-01)

ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol
by: Atara I. Ntekim, et al.
Published: (2020-11-01)

Trastuzumab for the treatment of primary HER2-positive breast cancer in HER2-positive women: a single technology appraisal
by: S Ward, et al.
Published: (2009-06-01)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
by: Celia Nieto, et al.
Published: (2019-06-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
by: Page E. Blas, et al.
Published: (2024-03-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
by: Caroline Rönnlund, et al.
Published: (2024-02-01)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: PLOS ONE Staff
Published: (2020-01-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
by: María F. Mercogliano, et al.
Published: (2017-12-01)

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
by: Celia Nieto, et al.
Published: (2020-08-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
by: Mengqi Zhang, et al.
Published: (2022-12-01)

Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study
by: Jean-Philippe Jacquin, et al.
Published: (2020-02-01)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer.
by: Gijsen, M, et al.
Published: (2010)